Diabetic macular edema (DME) is the most common cause of vision loss in people with diabetes and the leading cause of blindness among working-age adults in deve…
Medically reviewed by MedCentralHub Medical Review Board, Licensed Pharmacists & Physicians ·
Diabetic macular edema (DME) is the most common cause of vision loss in people with diabetes and the leading cause of blindness among working-age adults in developed countries. It occurs when damaged retinal blood vessels leak fluid and proteins into the macula, causing swelling and distortion of central vision. DME affects approximately 750,000 Americans and 21 million people worldwide. It can occur at any stage of diabetic retinopathy. With the advent of anti-VEGF therapy, most patients can maintain or improve vision, but ongoing treatment and tight metabolic control are required.
This information is for educational purposes only. Always consult a qualified healthcare professional for diagnosis and personalized treatment.
Blurred or hazy central vision
Difficulty reading or performing tasks requiring fine detail
Colors appearing washed out or less vivid
Straight lines appearing wavy or distorted (metamorphopsia)
Central blind spot in advanced cases
Floaters from associated diabetic retinopathy hemorrhages
Often asymptomatic in early stages — detected only on screening exam
Dilated fundus examination with biomicroscopy
Optical coherence tomography (OCT) — gold standard: measures central retinal thickness, subretinal fluid, intraretinal cysts, disorganization of retinal inner layers (DRIL)
Fluorescein angiography (FA) — identifies capillary non-perfusion, leakage patterns (focal vs. diffuse), and macular ischemia
OCTA — non-invasive assessment of superficial and deep capillary plexus
Classification: center-involving DME (CI-DME) vs. non-center-involving — critical for treatment decisions
Visual acuity assessment (ETDRS chart or Snellen equivalent) at each visit
Aflibercept (Eylea)
Anti-VEGF intravitreal injection. 2 mg monthly x5, then every 2 months. VISTA and VIVID trials: superior to laser. High-dose Eylea HD 8 mg approved for extended intervals. First-line for center-involving DME.
Ranibizumab (Lucentis)
0.3 mg monthly for DME. RIDE and RISE trials demonstrated superior visual acuity gains vs. sham. FDA-approved specifically for DME.
Faricimab (Vabysmo)
Dual VEGF-A and Ang-2 inhibitor. 6 mg monthly x4, then personalized dosing interval up to q16w. YOSEMITE and RHINE trials: non-inferior to aflibercept with extended intervals.
Intravitreal Corticosteroids (Triamcinolone, Dexamethasone Implant)
Ozurdex (dexamethasone implant 0.7 mg) for phakic patients with DME. Particularly effective in pseudophakic patients. Risk of IOP elevation and cataract with repeated use. Used when anti-VEGF is inadequate.
Laser Photocoagulation
Focal/grid laser for non-center-involving DME or as adjunct to anti-VEGF. No longer first-line since anti-VEGF superiority established. Subthreshold micropulse laser has fewer side effects.
Achieve and maintain HbA1c target (<7% for most patients) — most important intervention
Blood pressure control (<130/80 mmHg) — reduces progression of DME and retinopathy
Lipid control: statins reduce hard exudate formation; fenofibrate has shown retinopathy benefit (FIELD, ACCORD-Eye trials)
Annual dilated eye exams (more frequent when DME is active or poorly controlled)
Smoking cessation
Regular aerobic exercise improves insulin sensitivity and microvascular health
Monitor blood glucose consistently and report rapid HbA1c improvements to ophthalmologist (paradoxical worsening possible)
CPAP therapy if obstructive sleep apnea present
Prognosis
With consistent anti-VEGF therapy, approximately 30–40% of patients gain ≥15 ETDRS letters of visual acuity, and most maintain baseline vision. Without treatment, 25–30% of patients with CI-DME lose ≥15 letters within 3 years. Long-term visual outcomes are tied to glycemic and blood pressure control, and to treatment adherence. Eyes with macular ischemia or DRIL have worse visual prognosis. Bilateral involvement is common, and DME may recur or persist requiring indefinite treatment. GLP-1 receptor agonists (semaglutide) may have emerging roles in reducing diabetic retinopathy progression.
Diabetic Macular Edema is a medical condition classified under Ophthalmology. Diabetic macular edema (DME) is the most common cause of vision loss in people with diabetes and the leading cause of blindness among working-age adults in developed countries. It occurs when damaged retinal blood vessels leak fluid and proteins into the macula, causing swelling and distortion of central vision. Understanding Diabetic Macular Edema is essential for patients, families, and healthcare providers to ensure timely diagnosis, appropriate treatment, and optimal outcomes.
Last reviewed by MedCentralHub Medical Review Board · MedCentralHub Editorial Policy
Medical Disclaimer
The information on this page is for educational purposes only and is not intended as medical advice, diagnosis, or treatment. Always consult your doctor or a qualified healthcare provider with any questions about a medical condition.